The Asian Scientist 100
Di Li
Institution
National Astronomical Observatories of the Chinese Academy of Sciences
Country
China
Field
Aerospace & Astronomy
Li received the Marcel Grossmann Award for his pioneering contributions in the field of fast radio bursts. Li is the first scientist in China to receive this prize for research conducted within China.
(Photo: The Paper)
AWARDS
- Marcel Grossmann Award
Related articles
Compliments Help People Perform Tasks Better, Study
Japanese scientists have found evidence that people performing tasks appear to perform better when another person compliments them.
Soft Tissue X-Ray Could Help Cystic Fibrosis Patients
A new X-ray system that allows the imaging of soft tissue could be used to non-invasively track the effectiveness of treatments for cystic fibrosis.
How X-Rays Are Absorbed By Matter
An X-ray beam can ionize matter in just a few hundred femtoseconds, researchers say.
10 Medical Devices That Changed The World
Medical devices may sound like a modern invention, but they in fact have helped us manage and treat diseases for centuries. Here are our top ten picks of medical gadgets that play a significant role in our lives, many of them so ubiquitous that we sometimes take them for granted.
WuXi & Lilly To Develop Cardiovascular Drug In China
As part of Lilly's ‘In China, For China’ strategy, the small molecule drug is intended to help the 276 million Chinese patients affected by high cholesterol.
WuXi Begins Construction Of New Facility In Philadelphia
WuXi PharmaTech's intended 45,000 square feet facility will be for the manufacture of cell-based therapeutics.
WuXi To Offer Foundation’s Genomic Profiling In China
WuXi has been licensed to perform the FoundationOne® assay, providing the best-in-class genomics platform to biopharmaceuticals in China.
Enhanced Genomics Services For Chinese Researchers
WuXi's customers can look forward to enhanced sequence analysis capabilities thanks to a partnership with NextCODE Health.
WuXi To Build Third Cell Therapy Facility
The company's third cell therapy manufacturing facility will focus on chimeric antigen receptor T cells for cancer immunotherapy.